α/β-Hydrolase Domain (ABHD) Inhibitors as New Potential Therapeutic Options against Lipid-Related Diseases

Area of Science:

• Biochemistry
• Pharmacology
• Molecular Biology

Background:

• Altered lipid metabolism is linked to severe diseases including cancer, obesity, cardiovascular diseases, diabetes, and neurodegenerative disorders.
• Targeting dysregulated lipid metabolism pathways is a key therapeutic strategy.
• Alpha/beta-hydrolase domain (ABHD) enzymes are critical regulators of lipid signaling and metabolism.

Purpose of the Study:

• To summarize research progress on the development of ABHD inhibitors and modulators.
• To highlight design strategies, structure-activity relationships, and mechanisms of action for ABHD ligands.
• To review biological studies of key ABHD modulators.

Main Methods:

• Literature review and synthesis of experimental evidence.
• Analysis of structure-activity relationships (SAR) of ABHD inhibitors.
• Examination of the biological roles and action mechanisms of ABHD modulators.

Main Results:

• ABHD enzymes are integral to lipid metabolism and the endocannabinoid system, particularly in regulating 2-arachidonoylglycerol.
• Various design strategies have been employed to develop specific ABHD inhibitors and modulators.
• Structure-activity relationship studies provide insights into ligand design for therapeutic intervention.

Conclusions:

• ABHD enzymes represent significant therapeutic targets for a range of severe diseases.
• The development of ABHD inhibitors and modulators is a rapidly advancing field with therapeutic potential.
• Further research into ABHD ligands and their biological effects is warranted for drug discovery.